Praecis Pharmaceuticals Incorporated Presents Interim Clinical Data On PPI-2458 At The 18th EORTC-NCI-AACR Symposium

WALTHAM, Mass.--(BUSINESS WIRE)--PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS) today announced that it is presenting interim clinical data from an ongoing phase 1 trial of its investigational compound, PPI-2458, at the 18th EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics” being held from Tuesday, November 7 to Friday, November 10, 2006 at the Prague Congress Centre in Prague, Czech Republic. The data being presented is entitled “A Phase 1 Dose Escalation Safety & Tolerance Study of PPI-2458 in Subjects with Non-Hodgkin’s Lymphoma or Solid Tumors” (Abstract #139). Additionally, PRAECIS is presenting research on the potential role of PPI-2458 in melanoma in a poster entitled “Effects of PPI-2458, an inhibitor of methionine aminopeptidase type-2 on growth of melanoma and expression of MITF” (Abstract #349). The posters may be viewed on the Company’s website (http://www.praecis.com) in the “Investors” section, under “Presentations.”

Back to news